PR Newswire Asia's news > Infectious Disease Control

 < Previous page   |   Title only   |   Print 
     
Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization
"Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" "While maintaining the current process for emergency ...
2024-08-28T    Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration
-  Develops Novaplex TM MPXV/OPXV Assay and Novaplex TM HSV-1&2/VZV/MPXV Assay ...
2024-08-26T    Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
PHYLEX VACCINE ON TRACK TO COMBAT DEADLY NIPAH VIRUS WITH POSITIVE RESULTS OF IMMUNOGENICITY STUDY
DEL MAR, Calif. , Aug. 6, 2024 /PRNewswire/ -- Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in ...
2024-08-06T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
 < Previous page 

 

88iv | Home |  Login
Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer
Copyright (C) 2024
Suntek Computer Systems Limited.
All rights reserved